Skip to content
Baker Capital StrategiesMARKETS. FILINGS. PERSPECTIVE.
Powered by THEMA

Baker Capital Strategies

Free Registration

Register for access to news, tools, alerts and reports.

THEMA Basic included at launch.

Use at least 8 characters.

Home/The Filing Wire/Immutep Ltd/ 6-K

SEC Filing · 6-K

Immutep Ltd

PRRUFOTCEQUITYCurrent

SEC Filing

Filed Sep 22, 2026Accepted Sep 22, 2026, 6:01 AM EDTCIK 1506184Accession 0001193125-26-397189
View company →Permanent SEC source ↗
Share

Company context

Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3’s ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit www.immutep.com.

Current securities

IMMPNASDAQ · ADR · CurrentPRRUFOTC · EQUITY · Current

Recent company filings

  1. 6-K filingSep 11, 2026
  2. 6-K filingSep 2, 2026
  3. 6-K filingAug 3, 2026
  4. 6-K filingJul 14, 2026
  5. 6-K filingJun 5, 2026

As-filed source

Primary evidence
As filedOpen full document ↗